Physician profile
Mark S Wright
NPI 1154448991
$637,028.02
in general payments reported to CMS, 2019-2025
31 companies · $161K in 2025
The $161K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $11K · 2021: $66K · 2022: $113K · 2023: $111K · 2024: $146K · 2025: $161K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $184K · Honoraria: $116K · Consulting Fee: $76K · Travel and Lodging: $20K · Food and Beverage: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,581 · Education: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $184,026.38 |
| Honoraria | $116,050.00 |
| Consulting Fee | $75,592.50 |
| Travel and Lodging | $20,412.72 |
| Food and Beverage | $11,786.51 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,581.25 |
| Education | $463.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $165,197.01 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $129,169.72 | 2022-2025 | Auvelity |
| Alkermes, INC. | $126,590.01 | 2021-2025 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $96,651.21 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Tris Pharma INC | $49,605.53 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Neurocrine Biosciences, INC. | $49,461.41 | 2019-2025 | Ingrezza |
| Noven Pharmaceuticals, INC. | $8,162.79 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $5,118.46 | 2019-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $2,802.62 | 2023-2025 | Xelstrym, Secuado |
| Corium, LLC | $799.11 | 2021-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $591.98 | 2019-2025 | Rexulti |
| Lundbeck LLC | $520.22 | 2019-2025 | Rexulti |
| Neos Therapeutics, Lp | $388.88 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $377.34 | 2019-2025 | Trintellix |
| Bausch Health US, LLC | $304.15 | 2019-2025 | Wellbutrin, Aplenzin |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $276.36 | 2019-2023 | Spravato |
| Allergan, INC. | $263.04 | 2019 | |
| Sunovion Pharmaceuticals INC. | $125.65 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $117.93 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $85.64 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.00 | 2021-2024 | Caplyta |
| Abbvie INC. | $75.16 | 2021-2023 | Vraylar |
| Vanda Pharmaceuticals INC. | $56.77 | 2022-2025 | Fanapt |
| Vertical Pharmaceuticals, LLC | $47.60 | 2019-2025 | Relexxii |
| Shire North American Group INC | $39.95 | 2019 | |
| Neuronetics, INC. | $28.64 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Sage Therapeutics, LLC | $23.73 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $20.59 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $14.66 | 2019 | |
| Pernix Therapeutics Holdings, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.